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Human Bocavirus was detected in 18 (1.5%) of 1,209
respiratory specimens collected in 2003 and 2004 in
Canada. The main symptoms of affected patients were
cough (78%), fever (67%), and sore throat (44%). Nine
patients were hospitalized; of these, 8 (89%) were <5 years
of age.
A
new parvovirus, human Bocavirus (HBoV), was
recently identified in Sweden (1). The virus was iden-
tified in clinical specimens from infants and children with
respiratory tract illness. Phylogenetic analyses of the com-
plete genome of HBoV showed that that the virus is most
closely related to canine minute virus and bovine par-
vovirus, which are members of the genus Bocavirus, fam-
ily Parvoviridae (1). To date, the only parvovirus known to
be pathogenic in humans is B19, which is responsible for
Fifth disease in children (2). The role of HBoV in respira-
tory tract illnesses is unknown. We retrospectively investi-
gated HBoV in Canadian patients with acute respiratory
infection (ARI) in 2003 and 2004 to assess the impact of
HBoV infections on respiratory tract illnesses and identify
the signs and symptoms of this illness.
The Study
Atotal of 1,209 specimens from patients with ARI from
January 2003 to December 2004 were tested for HBoV.
The specimens originated from the Saskatchewan provin-
cial public health laboratories. Specimen types analyzed
included throat swabs, nasopharyngeal swabs, nasopha-
ryngeal aspirates, and auger suctions. All specimens were
negative for influenza viruses A and B; parainfluenza
viruses 1, 2, and 3; adenovirus; and respiratory syncytial
virus (RSV) by direct or indirect fluorescence assays or
virus isolation and for human metapneumovirus (HMPV)
by reverse transcription–polymerase chain reaction.
Specimens were collected from all age groups: 290 (24%)
from those <5 years of age, 59 (5%) from those 6–10 years
of age, 90 (7.4%) from those 11–15 years of age, 86 (7.1%)
from those 16–20 years of age, 358 (29.6%) from those
21–50 years of age, and 324 (27%) from those >50 years
of age, The age of the patients was unknown for 2 (0.2%)
specimens.
HBoV was detected by polymerase chain reaction
(PCR) using primers specific for 2 different regions of the
genome. The screening primers 188F (2281-5′-GAC-
CTCTGTAAGTACTATTAC-3′-2301) and 542R (2634-5′-
CTCTGTGTTGACTGAATACAG-3′-2614), reported by
Allander et al. (1), were based on the sequence of the puta-
tive noncapsid protein 1 (NP-1) gene. The second set of
primers, VP1/VP2F (4492-5′-GCAAACCCATCACTCT-
CAATGC-3′-4513) and VP1/VP2R (4895-5′-GCTCTCT-
CCTCCCAGTGACAT-3′-4875), was used for confir-
mation and was based on the published HBoV putative
VP1/VP2 gene sequences (DQ000495) (1). Viral DNA
was extracted from 285 µL of original samples with a
BioRobot MDx and the QiAamp Virus BioRobot MDX kit
(Qiagen, Valencia, CA, USA). We used 5 µL of DNA in a
volume of 50 µL containing 20 pmol of each primer. The
thermocycler conditions were 95°C for 15 min for activa-
tion of HotStartTaq DNA polymerase (Qiagen); 35 cycles
of 94°C for 1 min, 54°C for 1 min, and 72°C for 2 min; and
extension at 72°C for 10 min. Nucleotide sequences of NP-
1 gene amplicons were determined with an ABI 377
Sequencer and a fluorescent dye terminator kit (Applied
Biosystems, Foster City, CA, USA). DNA sequences were
assembled and analyzed with SEQMAN, EDITSEQ, and
MEGALIGN programs in Lasergene (DNASTAR,
Madison, WI, USA). To avoid cross-contamination, speci-
men processing, DNAextraction, amplification, and analy-
ses were conducted in different rooms. For DNA
extraction and PCR procedures, we included 12 negative
controls per 96-well plate.
Atotal of 18 (1.5%) of the 1,209 specimens tested were
positive for HBoV by PCR. HBoV activity was found
throughout the year with no apparent seasonal prevalence
(Table 1). The sex distribution of patients was 61% (11)
male and 39% (7) female (Table 2). Patients with HBoV
ranged in age from 10 months to 60 years (median 11.5
years), and no significant difference in infection rates was
observed between age groups. 
The main clinical symptoms were cough (78%), fever
(67%), and sore throat (44%) (Table 2). Other clinical
symptoms included flulike symptoms (28%), headache
(22%), nausea (17%), and myalgia (11%). Five patients
had rhinitis, 1 had pneumonia, and 1 had bronchiolitis.
One patient had rhinitis, bronchiolitis, and pneumonia, and
1 patient had rhinitis and pneumonia. Nine (50%) HBoV
patients were hospitalized; 8 (89%) were <5 years of age,
and 1 was between 21 and 50 years of age. The incidence
of lower respiratory tract infection was lower in outpa-
tients: 1 with bronchiolitis and no pneumonia (Table 2).
Although the infection rates were similar in all age groups,
a significant increase in hospitalization rates was seen in
those <5 years of age compared with those >6 years of age
(8/8 vs. 1/10, p = 0.001) (Table 2). All patients with
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Nucleotide sequences were determined for nucleotides
2342–2581 that encode the NP-1 gene of HBoV (GenBank
accession nos. DQ267760–DQ267775). No differences in
nucleic acid sequences were found between different
Canadian isolates. These isolates were also identical to 2
Swedish isolates (ST1 and ST2, GenBank accession nos.
DQ000495–DQ000496) (1). 
Conclusions
Although a causal relationship still needs to be demon-
strated by including a control group of healthy persons,
detection of HBoV in respiratory tract specimens from
patients with undiagnosed ARI suggests that this virus may
be associated with respiratory illness. This finding sup-
ports those of Allander et al. with regard to the association
of HBoV with respiratory disease (1). It also demonstrates
that HBoV was present in Canada in 2003 and 2004, which
suggests that it may be circulating worldwide. Since this
study used only samples from ARI patients who tested
negative for influenza viruses A and B, parainfluenza
viruses 1–3, adenovirus, RSV, and HMPV, dual infection
cannot be excluded. In addition, whether HBoV is present
asymptomatically in humans cannot be excluded because
samples from healthy persons were not tested.
Allander et al. reported HBoV only in infants and chil-
dren, which was probably the result of testing fewer spec-
imens from adults patients (1). Most respiratory viruses
show a seasonal distribution with peak activity in winter.
Human parvovirus B19, the only parvovirus that is patho-
genic in humans, is also seasonal, with peak occurrences in
spring and summer (3). In contrast, no seasonal prevalence
was observed for HBoV infection; the virus was found
throughout the year. The lack of seasonality observed for
HBoV may have been caused by the low prevalence in this
study. Thus, additional year-round studies are needed to
better understand the epidemiology of HBoV. Most (89%)
hospitalizations were in persons <5 years of age, which
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ness in infants and children, similar to disease caused by
RSV (4,5), HMPV (6,7), human coronavirus NL63 (8–14),
and human coronavirus 229E (15). More comprehensive
studies with data on prevalence, risk factors, and use of
health services are needed to determine the role of HBoV
in ARI and its effect on the healthcare system.
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